Mevastatin can cause G1 arrest and induce apoptosis in pulmonary artery smooth muscle cells through a p27kip1-independent pathway

Circulation Research

Volumn 92, Issue 5, 2003, Pages 501-509

  Fouty, Brian W ^a   Rodman, David M ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

HMG CoA reductase; p27Kip1; Pulmonary hypertension; Vascular smooth muscle

Indexed keywords

COMPACTIN; CYCLIN DEPENDENT KINASE 2; CYCLIN E; CYCLIN E KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHOTRANSFERASE; PROTEIN P27; THREONINE; UNCLASSIFIED DRUG; CDKN1B PROTEIN, MOUSE; CDKN1B PROTEIN, RAT; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E DEPENDENT KINASE; CYCLIN E-DEPENDENT KINASE; DNA; DRUG DERIVATIVE; MEVINOLIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ARTERY MUSCLE; ARTICLE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFECT; ENZYME ACTIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PULMONARY HYPERTENSION; RAT; SMOOTH MUSCLE FIBER; ANIMAL; APOPTOSIS; BIOSYNTHESIS; CELL CULTURE; CULTURE MEDIUM; CYTOLOGY; GENETICS; KINETICS; METABOLISM; MOUSE; MUTATION; PHYSIOLOGY; PULMONARY ARTERY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; VASCULAR SMOOTH MUSCLE;

ANIMALS; APOPTOSIS; CELL CYCLE PROTEINS; CELLS, CULTURED; CULTURE MEDIA; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; DNA; G1 PHASE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KINETICS; LOVASTATIN; MALE; MICE; MUSCLE, SMOOTH, VASCULAR; MUTATION; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 0037459124     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000061180.03813.0F     Document Type: Article

References (36)

1. Rabinovitch M, Gamble WJ, Miettinen OS, Reid L. Age and sex influence on pulmonary hypertension of chronic hypoxia and on recovery. Am J Physiol. 1981;240:H62-H72.
2. Meyrick BO, Perkett EA. The sequence of cellular and hemodynamic changes of chronic pulmonary hypertension induced by hypoxia and other stimuli. Am Rev Respir Dis. 1989;140:1486-1489.
3. Chazova I, Loyd JE, Zhdanov VS, Newman JH, Belenkov Y, Meyrick B. Pulmonary artery adventitial changes and venous involvement in primary pulmonary hypertension. Am J Pathol. 1995;146:389-397.
4. Jones R, Reid L. Vascular remodeling in clinical and experimental pulmonary hypertension. In: Bishop JE, Reeves JT, Laurent GJ, eds. Pulmonary Vascular Remodeling. London, UK: Portland Press Research Monograph VI; 1995:47-115.
5. Rabinovitch M, Bothwell T, Hayakawa BN, Williams WG, Truster GA, Rowe RD, Olley PM, Cutz E. Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension: a correlation of light with scanning electron microscopy and transmission electron microscopy. Lab Invest. 1986;55:632-653.
6. Gordon D, Reidy MA, Benditt EP, Schwartz SM. Cell proliferation in human coronary arteries. Proc Natl Acad Sci U S A. 1990;87:4600-4604.
7. 1 cyclin-dependent kinases. Genes Dev. 1995;9:1149-1163.
8. 1-phase progression. Genes Dev. 1999;13:1501-1512.
9. Pavletich NP. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol. 1999;287:821-828.
10. Lundberg AS, Weinberg RA. Control of the cell cycle and apoptosis. Eur J Cancer. 1999;35:1886-1894.
11. Vidal A, Koff A. Cell-cycle inhibitors: three families united by a common cause. Gene. 2000;247:1-15.
12. Roussel MF. The INK4 family of cell cycle inhibitors in cancer. Oncogene. 1999;18:5311-5317.
13. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
14. Crouse JR 3rd, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, McGovern ME, Furberg CD. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol. 1995;75:455-459.
15. Crouse JR 3rd, Byington RP, Furberg CD. HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. Atherosclerosis. 1998;138:11-24.
16. Oliver MF. Statins prevent coronary heart disease. Lancet. 1995;346: 1378-1379.
17. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res. 2000;47:648-657.
18. Kohno M, Shinomiya K, Abe S, Noma T, Kondo I, Oshita A, Takeuchi H, Takagi Y, Yukiiri K, Mizushige K, Ohmori K. Inhibition of migration and proliferation of rat vascular smooth muscle cells by a new HMG-CoA reductase inhibitor, pitavastatin. Hypertens Res. 2002;25:279-285.
19. Lefer AM, Scalia R, Lefer DJ. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res. 2001;49:281-287.
20. Vidal A, Millard SS, Miller JP, Koff A. Rho activity can alter the translation of p27 mRNA and is important for Ras V12-induced transformation in a manner dependent on p27 status. J Biol Chem. 2002;277:16433-16440.
21. 1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci U S A. 1999;96:7797-7802.
22. Park WH, Lee YY, Kim ES, Seol JG, Jung CW, Lee CC, Kim BK. Lovastatin-induced inhibition of HL-60 cell proliferation via cell cycle arrest and apoptosis. Anticancer Res. 1999;19:3133-3140.
23. Kip1. J Biol Chem. 1999;274:21926-21931.
24. Kip1 is important in modulating pulmonary artery smooth muscle cell proliferation. Am J Respir Cell Mol Biol. 2001;25:652-658.
25. 1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene. 1998;17:2393-2402.
26. Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol. 2002;3:11-20.
27. Zini N, Trimarchi C, Claudio PP, Stiegler P, Marinelli F, Maltarello MC, La Sala D, De Falco G, Russo G, Ammirati G, Maraldi NM, Giordano A, Cinti C. pRb2/p130 and p107 control cell growth by multiple strategies and in association with different compartments within the nucleus. J Cell Physiol. 2001;189:34-44.
28. Kip1-deficient cells. Curr Biol. 1999;9:163-173.
29. Gu Y, Rosenblatt J, Morgan DO. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J. 1992;11:3995-4005.
30. Sun J, Qian Y, Chen Z, Marfurt J, Hamilton AD, Sebti SM. The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors: a potential mechanism for GGTI-298 antitumor activity. J Biol Chem. 1999;274:6930-6934.
31. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev. 1994;8:9-22.
32. Kip1 in vascular smooth muscle cell migration. Circulation. 2001;104:852-855.
33. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009.
34. Wachtershauser A, Akoglu B, Stein J, HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis. 2001;22:1061-1067.
35. kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol. 1999;154:313-323.
36. Cool CD, Stewart JS, Werahera P, Miller GJ, Williams RL, Voelkel NF, Tuder RM. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers: evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol. 1999;155:411-419.